Your browser doesn't support javascript.
loading
Identification of an Adamantyl Azaquinolone JNK Selective Inhibitor.
Haynes, Nancy-Ellen; Scott, Nathan R; Chen, Li C; Janson, Cheryl A; Li, Jia Kui; Lukacs, Christine M; Railkar, Aruna; Tozzo, Effie; Whittard, Toni; Brown, Nicholas F; Cheung, Adrian Wai-Hing.
Affiliation
  • Haynes NE; Hoffmann-La Roche Inc. , pRED, Pharma Research & Early Development, DTA Metabolism, 340 Kingsland Street, Nutley, New Jersey 07110, United States.
  • Scott NR; Hoffmann-La Roche Inc. , pRED, Pharma Research & Early Development, DTA Metabolism, 340 Kingsland Street, Nutley, New Jersey 07110, United States.
  • Chen LC; Hoffmann-La Roche Inc. , pRED, Pharma Research & Early Development, DTA Metabolism, 340 Kingsland Street, Nutley, New Jersey 07110, United States.
  • Janson CA; Hoffmann-La Roche Inc. , pRED, Pharma Research & Early Development, DTA Metabolism, 340 Kingsland Street, Nutley, New Jersey 07110, United States.
  • Li JK; Hoffmann-La Roche Inc. , pRED, Pharma Research & Early Development, DTA Metabolism, 340 Kingsland Street, Nutley, New Jersey 07110, United States.
  • Lukacs CM; Hoffmann-La Roche Inc. , pRED, Pharma Research & Early Development, DTA Metabolism, 340 Kingsland Street, Nutley, New Jersey 07110, United States.
  • Railkar A; Hoffmann-La Roche Inc. , pRED, Pharma Research & Early Development, DTA Metabolism, 340 Kingsland Street, Nutley, New Jersey 07110, United States.
  • Tozzo E; Hoffmann-La Roche Inc. , pRED, Pharma Research & Early Development, DTA Metabolism, 340 Kingsland Street, Nutley, New Jersey 07110, United States.
  • Whittard T; Hoffmann-La Roche Inc. , pRED, Pharma Research & Early Development, DTA Metabolism, 340 Kingsland Street, Nutley, New Jersey 07110, United States.
  • Brown NF; Hoffmann-La Roche Inc. , pRED, Pharma Research & Early Development, DTA Metabolism, 340 Kingsland Street, Nutley, New Jersey 07110, United States.
  • Cheung AW; Hoffmann-La Roche Inc. , pRED, Pharma Research & Early Development, DTA Metabolism, 340 Kingsland Street, Nutley, New Jersey 07110, United States.
ACS Med Chem Lett ; 3(9): 764-8, 2012 Sep 13.
Article in En | MEDLINE | ID: mdl-24900545
3-[4-((1S,2S,3R,5S,7S)-5-Hydroxyadamantan-2-ylcarbamoyl)benzyl]-4-oxo-1-phenyl-1,4-dihydro-[1,8]naphthyridine-2-carboxylic acid methyl ester (4) was identified as a novel, druglike and selective quinolone pan JNK inhibitor. In this communication, some of the structure-activity relationship of the azaquinolone analogues leading to 4 is discussed. The focus is on how changes at the amide functionality affected the biochemical potency, cellular potency, metabolic properties, and solubility of this class of JNK inhibitors. Optimization of these properties led to the identification of the adamantyl analogue, 4. 4 achieved proof of mechanism in both rat and mouse TNF-α challenge models.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Diagnostic_studies Language: En Journal: ACS Med Chem Lett Year: 2012 Document type: Article Affiliation country: United States Country of publication: United States

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Diagnostic_studies Language: En Journal: ACS Med Chem Lett Year: 2012 Document type: Article Affiliation country: United States Country of publication: United States